These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25787321)

  • 1. [Acute myeloid leukemia].
    Döhner K; Paschka P; Döhner H
    Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acute myeloid leukemia. Genetic diagnostics and molecular therapy].
    Schlenk RF; Döhner K; Döhner H
    Internist (Berl); 2013 Feb; 54(2):171-8. PubMed ID: 23358744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute myeloid Leukemia].
    Braess J
    Dtsch Med Wochenschr; 2016 Nov; 141(24):1748-1751. PubMed ID: 27835920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute myeloid leukemia].
    Ohtake S
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2175-9. PubMed ID: 18079616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
    DiNardo C; Lachowiez C
    Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology Consultation on Gene Mutations in Acute Myeloid Leukemia.
    Ziai JM; Siddon AJ;
    Am J Clin Pathol; 2015 Oct; 144(4):539-54. PubMed ID: 26386075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A concise review on the molecular genetics of acute myeloid leukemia.
    Padmakumar D; Chandraprabha VR; Gopinath P; Vimala Devi ART; Anitha GRJ; Sreelatha MM; Padmakumar A; Sreedharan H
    Leuk Res; 2021 Dec; 111():106727. PubMed ID: 34700049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [What is recommended in the treatment of acute myeloid leukemia?].
    Thol F
    Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.
    Kadia TM; Ravandi F; Cortes J; Kantarjian H
    JAMA Oncol; 2015 Sep; 1(6):820-8. PubMed ID: 26181162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline treatment of acute myeloid leukemia in adults.
    Tamamyan G; Kadia T; Ravandi F; Borthakur G; Cortes J; Jabbour E; Daver N; Ohanian M; Kantarjian H; Konopleva M
    Crit Rev Oncol Hematol; 2017 Feb; 110():20-34. PubMed ID: 28109402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gene mutations in acute myeloid leukemia].
    Yamaguchi H
    Rinsho Ketsueki; 2016; 57(12):2535-2542. PubMed ID: 28090023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular markers in acute myeloid leukaemia.
    Kühnl A; Grimwade D
    Int J Hematol; 2012 Aug; 96(2):153-63. PubMed ID: 22791509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New agents for the treatment of acute myeloid leukemia.
    Tallman MS
    Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate-risk acute myeloid leukemia therapy: current and future.
    Döhner K; Paschka P
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):34-43. PubMed ID: 25696832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
    Guenounou S; Delabesse E; Récher C
    Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.